Neurite Orientation Dispersion and Density Imaging for Assessing Acute Inflammation and Lesion Evolution in MS

References

1. 1.↵
   1. Thompson AJ,
   2. Banwell BL,
   3. Barkhof F, et al

   . Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018;17:162–73 doi:10.1016/S1474-4422(17)30470-2 pmid:29275977

   CrossRefPubMed
2. 2.↵
   1. Filippi M,
   2. Rocca MA,
   3. Ciccarelli O, et al

   . MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol 2016;15:292–303 doi:10.1016/S1474-4422(15)00393-2

   CrossRefPubMed
3. 3.↵
   1. De Groot CJ,
   2. Bergers E,
   3. Kamphorst W, et al

   . Post-mortem MRI-guided sampling of multiple sclerosis brain lesions: increased yield of active demyelinating and (p)reactive lesions. Brain 2001;124:1635–45 doi:10.1093/brain/124.8.1635 pmid:11459754

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Cercignani M,
   2. Bozzali M,
   3. Iannucci G, et al

   . Intra-voxel and inter-voxel coherence in patients with multiple sclerosis assessed using diffusion tensor MRI. J Neurol 2002;249:875–83 doi:10.1007/s00415-002-0752-y pmid:12140672

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Gulani V,
   2. Calamante F,
   3. Shellock FG, et al

   ; International Society for Magnetic Resonance in Medicine. Gadolinium deposition in the brain: summary of evidence and recommendations. Lancet Neurol 2017;16:564–70 doi:10.1016/S1474-4422(17)30158-8 pmid:28653648

   CrossRefPubMed
6. 6.↵
   1. Zhang H,
   2. Schneider T,
   3. Wheeler-Kingshott CA, et al

   . NODDI: practical in vivo neurite orientation dispersion and density imaging of the human brain. Neuroimage 2012;61:1000–16 doi:10.1016/j.neuroimage.2012.03.072 pmid:22484410

   CrossRefPubMed
7. 7.↵
   1. Schneider T,
   2. Brownlee W,
   3. Zhang H, et al

   . Sensitivity of multi-shell NODDI to multiple sclerosis white matter changes: a pilot study. Funct Neurol 2017;32:97–101 doi:10.11138/fneur/2017.32.2.097 pmid:28676143

   CrossRefPubMed
8. 8.↵
   1. Caverzasi E,
   2. Papinutto N,
   3. Castellano A, et al

   . Neurite orientation dispersion and density imaging color maps to characterize brain diffusion in neurologic disorders. J Neuroimaging 2016;26:494–98 doi:10.1111/jon.12359 pmid:27214558

   CrossRefPubMed
9. 9.↵
   1. Grussu F,
   2. Schneider T,
   3. Tur C, et al

   . Neurite dispersion: a new marker of multiple sclerosis spinal cord pathology? Ann Clin Transl Neurol 2017;4:663–79 doi:10.1002/acn3.445 pmid:28904988

   CrossRefPubMed
10. 10.↵
    1. Granberg T,
    2. Fan Q,
    3. Treaba CA, et al

    . In vivo characterization of cortical and white matter neuroaxonal pathology in early multiple sclerosis. Brain 2017;140:2912–26 doi:10.1093/brain/awx247 pmid:29053798

    CrossRefPubMed
11. 11.↵
    1. Spanò B,
    2. Giulietti G,
    3. Pisani V, et al

    . Disruption of neurite morphology parallels MS progression. Neurol Neuroimmunol Neuroinflamm 2018;5:e502 doi:10.1212/NXI.0000000000000502 pmid:30345330

    Abstract/FREE Full Text
12. 12.↵
    1. De Santis S,
    2. Bastiani M,
    3. Droby A, et al

    . Characterizing microstructural tissue properties in multiple sclerosis with diffusion MRI at 7T and 3T: the impact of the experimental design. Neuroscience 2019;403:17–26 doi:10.1016/j.neuroscience.2018.03.048 pmid:29631021

    CrossRefPubMed
13. 13.↵
    1. Luo T,
    2. Oladosu O,
    3. Rawji KS, et al

    . Characterizing structural changes with devolving remyelination following experimental demyelination using high angular resolution diffusion MRI and texture analysis. J Magn Reson Imaging 2019;49:1750–59 doi:10.1002/jmri.26328 pmid:30230112

    CrossRefPubMed
14. 14.↵
    1. University of California, San Francisco MS-EPIC Team,
    2. Cree BA,
    3. Gourraud PA, et al

    . Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol 2016;80:499–510

    CrossRefPubMed
15. 15.↵
    1. University of California, San Francisco MS-EPIC Team,
    2. Cree BAC,
    3. Hollenbach JA, et al

    . Silent progression in disease activity-free relapsing multiple sclerosis. Ann Neurol 2019;85:653–66

    CrossRefPubMed
16. 16.↵
    1. Andersson JL,
    2. Skare S,
    3. Ashburner J

    . How to correct susceptibility distortions in spin-echo echo-planar images: application to diffusion tensor imaging. Neuroimage 2003;20:870–88 doi:10.1016/S1053-8119(03)00336-7 pmid:14568458

    CrossRefPubMedWeb of Science
17. 17.↵
    1. Smith SM,
    2. Jenkinson M,
    3. Woolrich MW, et al

    . Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004;23(Suppl 1):S208–19 doi:10.1016/j.neuroimage.2004.07.051 pmid:15501092

    CrossRefPubMedWeb of Science
18. 18.↵
    1. Garyfallidis E,
    2. Brett M,
    3. Amirbekian B, et al

    ; DIPY Contributors. DIPY, a library for the analysis of diffusion MRI data. Front Neuroinform 2014;8:8 doi:10.3389/fninf.2014.00008 pmid:24600385

    CrossRefPubMed
19. 19.↵
    1. Moore GR,
    2. Laule C,
    3. Mackay A, et al

    . Dirty-appearing white matter in multiple sclerosis: preliminary observations of myelin phospholipid and axonal loss. J Neurol 2008;255:1802–11 doi:10.1007/s00415-008-0002-z pmid:18821049

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Smith SM,
    2. Zhang Y,
    3. Jenkinson M, et al

    . Accurate, robust and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002;17:479–49 doi:10.1006/nimg.2002.1040 pmid:12482100

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Yi SY,
    2. Barnett BR,
    3. Torres-Velázquez M, et al

    . Detecting microglial density with quantitative multi-compartment diffusion MRI. Front Neurosci 2019;13:81 doi:10.3389/fnins.2019.00081 pmid:30837826

    CrossRefPubMed
22. 22.↵
    1. Popescu BF,
    2. Pirko I,
    3. Lucchinetti CF

    . Pathology of multiple sclerosis: where do we stand? Continuum (Minneap Minn) 2013;19:901–21 doi:10.1212/01.CON.0000433291.23091.65 pmid:23917093

    CrossRefPubMed
23. 23.↵
    1. Barkhof F,
    2. Brück W,
    3. De Groot CJ, et al

    . Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. Arch Neurol 2003;60:1073–81 doi:10.1001/archneur.60.8.1073 pmid:12925362

    CrossRefPubMedWeb of Science
24. 24.↵
    1. McCunn P,
    2. Gilbert KM,
    3. Zeman P, et al

    . Reproducibility of neurite orientation dispersion and density imaging (NODDI) in rats at 9.4 Tesla. PLoS One 2019;14:e0215974 doi:10.1371/journal.pone.0215974 pmid:1034490

    CrossRefPubMed
25. 25.↵
    1. Lassmann H

    . Multiple sclerosis pathology. Cold Spring Harb Perspect Med 2018;8:a028936 doi:10.1101/cshperspect.a028936 pmid:29358320

    Abstract/FREE Full Text
26. 26.↵
    1. Haider L,
    2. Zrzavy T,
    3. Hametner S, et al

    . The topography of demyelination and neurodegeneration in the multiple sclerosis brain. Brain 2016;139:807–15 doi:10.1093/brain/awv398 pmid:26912645

    CrossRefPubMed
27. 27.↵
    1. Thompson AJ,
    2. Baranzini SE,
    3. Geurts J, et al

    . Multiple sclerosis. Lancet 2018;391:1622–36 doi:10.1016/S0140-6736(18)30481-1 pmid:29576504

    CrossRefPubMed